Author name: comtex

PEOPLES FINANCIAL SERVICES CORP. Declares Third Quarter 2025 Dividend

The Board of Directors of Peoples Financial Services Corp. (“Peoples”) (NASDAQ: PFIS) declared a third quarter cash dividend of $0.6175 per share. The dividend is payable September 15, 2025 to shareholders of record August 29, 2025. https://mma.prnewswire.com/media/2738536/PEOPLES_FINANCIAL_SERVICES_CORP__LOGO.jpg Peoples Financial Services Corp. is the bank holding company of Peoples Security Bank and Trust Company, an independent […]

FLAGSTAR FINANCIAL, INC. DECLARES QUARTERLY CASH DIVIDENDS ON ITS COMMON STOCK AND PREFERRED STOCKS

Flagstar Financial, Inc. (NYSE: FLG) (the “Company”) today announced that its Board of Directors declared a quarterly cash dividend of $0.01 per share on the Company's common stock. The dividend is payable on September 17, 2025, to common stockholders of record as of September 7, 2025. https://mma.prnewswire.com/media/2543436/Flagstar_Financial_Logo.jpg In addition, the Board of Directors declared quarterly

Velo3D, Inc. Announces Reverse Stock Split

Velo3D, Inc. (OTC: VLDX), a leading provider of additive manufacturing technologies for mission-critical metal parts, today announced that its board of directors has approved a 1-for-15 reverse stock split of the Company's common stock, par value $0.00001 per share. The common stock is expected to begin trading on the OTCQX on July 28, 2025, on

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

(NasdaqGM:ATAI), Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active treatment arms compared to placebo, but did not meet statistical significance on the primary endpoint Inidascamine continues to exhibit a favorable safety and tolerability profile Full data set, including secondary endpoints and subgroup analyses will be forthcoming SOUTH SAN

Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer

(NASDAQ:CELC), MINNEAPOLIS, July 25, 2025 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the Company will hold a conference call and webcast on Monday, July 28, 2025 at 8:00 AM ET to disclose the topline results of the PIK3CA Wild-Type Cohort from the

IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025

(NasdaqGM:IRMD), ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) — IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 second quarter financial results before the market opens on Friday, August 1, 2025. Iradimed management will host a conference call the same day beginning at 11:00 a.m. Eastern Time to discuss those results

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia

Recognify Life Sciences Provides Update on Phase 2b Trial of Inidascamine in Patients with Cognitive Impairment Associated with Schizophrenia GlobeNewswire July 25, 2025 Initial results demonstrate numerical improvement of cognitive and functional measures with inidascamine across both active treatment arms compared to placebo, but did not meet statistical significance on the primary endpoint Inidascamine continues

Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer

Celcuity to Announce Topline Results for the PIK3CA Wild-Type Cohort from Phase 3 VIKTORIA-1 Trial in HR+/HER2- Advanced Breast Cancer GlobeNewswire July 25, 2025 MINNEAPOLIS, July 25, 2025 (GLOBE NEWSWIRE) — Celcuity Inc. (Nasdaq: CELC), a clinical-stage biotechnology company pursuing development of targeted therapies for oncology, today announced the Company will hold a conference call

IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025

IRADIMED CORPORATION to Hold Second Quarter of 2025 Financial Results Conference Call on August 1, 2025 GlobeNewswire July 25, 2025 ORLANDO, Fla., July 25, 2025 (GLOBE NEWSWIRE) — IRADIMED CORPORATION (NASDAQ: IRMD) announced today that the Company will release its 2025 second quarter financial results before the market opens on Friday, August 1, 2025. Iradimed

NurExone Biologic Finalist in Falling Walls Venture 2025 Global Platform Showcasing The World’s Most Promising Science-Based Start-Ups

(TSX-V:NRX),(Frankfurt:J90),(Boerse Stuttgart – Freiverkehr:J90),(Boerse Muenchen – Freiverkehr:J90),(OTC US:NRXBF),(Other OTC:NRXBF), TORONTO and HAIFA, Israel, July 25, 2025 (GLOBE NEWSWIRE) — NurExone Biologic Inc. (TSXV: NRX) (OTCQB: NRXBF) (FSE: J90) (“NurExone” or the “Company“) is pleased to announce that the Falling Walls Foundation has named the Company a finalist in Falling Walls Venture 2025, a global platform

Scroll to Top